Project Name

Innovation and Application of Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment Techniques and Schemes for Rheumatic Diseases

Main Contributing Institutions

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine)

Hunan Zhengqing Pharmaceutical Group Co., Ltd.

Macau University of Science and Technology

Zhejiang Chinese Medical University

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Hunan University of Chinese Medicine

Main Contributors

(Title, Contributing Institution, Employer)

1. Pan Hudan (Professor, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Main contribution: Overall person in charge of project application, responsible for overall design, presided over the implementation of major research projects, including clinical and basic research on integrated traditional Chinese and Western medicine diagnosis and treatment of rheumatic diseases, promoted the enhancement of clinical application of integrated traditional Chinese and Western medicine in the prevention and treatment of rheumatic diseases.)

2. Liu Liang (Academician, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Main contribution: Guided the overall design and organized the implementation of the project, provided integrated traditional Chinese and Western medicine guidance and technical support for the project.)

3. Wu Feichi ( Senior Pharmaceutical Engineer 、 Hunan Zhengqing Pharmaceutical Group Co., Ltd., Main contribution: Responsible for the technical development, clinical application, and promotion of Zhengqing Fengtongning drug.)

4. Zhu Yizhun (Professor, Macau University of Science and Technology, Main contribution: Focused on research into the pathogenesis of rheumatoid arthritis, drug targets, etc.)

5. Wen Chengping (Professor, Zhejiang Chinese Medical University , Main contribution: Focused on research into the discovery of systemic lupus erythematosus pathogenesis, development of integrated traditional Chinese and Western medicine diagnosis and treatment techniques, etc.)

6. Liang Qianqian (Professor, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Main contribution: Focused on research into the role and mechanism of traditional Chinese medicine in the prevention and treatment of rheumatoid arthritis and other rheumatic diseases.)

7. Liu Wei (Chief Physician, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Main contribution: Primarily participated in the clinical application and promotion research of Zhengqing Fengtongning and triple sequential therapy.)

8. Cai Xiong (Professor, Hunan University of Chinese Medicine, Main contribution: Primarily participated in research on the mechanism of traditional Chinese medicine in the prevention and treatment of rheumatoid arthritis.)

9. Huang Yuming (Senior Pharmaceutical Engineer, Hunan Zhengqing Pharmaceutical Group Co., Ltd., , Main contribution: Participated in the technical development, clinical application, and promotion research of Zhengqing Fengtongning drug.)

10. Wang Jingrong (Professor, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Main contribution: Primarily participated in the development of new technologies for diagnosing rheumatic diseases, such as IgG N-glycan.)

11. Zhou Hua (Professor, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Main contribution: Primarily participated in research on the pharmacological mechanism of Zhengqing Fengtongning against arthritis.)

12. Ding Qian (Assistant Professor, Macau University of Science and Technology, , Main contribution: Primarily participated in research on the pathogenesis of rheumatoid arthritis, drug targets, etc.)

13. Zhang Yun (Researcher, Zhejiang Chinese Medical University , Main contribution: Primarily participated in research on the discovery of systemic lupus erythematosus pathogenesis and the development of integrated traditional Chinese and Western medicine diagnosis and treatment techniques.)

14. Xie Ying (Professor, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Main contribution: Primarily participated in research on the mechanism of traditional Chinese medicine against arthritis.)

15. Chen Jinman (Assistant Researcher, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Main contribution: Primarily participated in research on the role and mechanism of traditional Chinese medicine in the prevention and treatment of rheumatoid arthritis and other rheumatic diseases.)

Representative Papers

Monograph Catalog

Papers 1： Pan  HD, Wang JR, Liang Y,   et al , Serum IgG glycan hallmarks of systemic lupus erythematosus, Engineering  2023,26(7):89-98.

Papers 2： HD Pan, RJ Guo, YM Ju, et al . A single bacterium restores the microbiome dysbiosis to protect bones from destruction in a rat model of rheumatoid arthritis. Microbiome  2019 Jul 17;7(1):107.

Papers 3： Ding Q, Hu W, Wang R,   et al . Signaling pathways in rheumatoid arthritis: implications for targeted therapy.'  Signal Transduct Target Ther . 2023 Feb 17;8(1):68.

Papers 4： S hi Y, Pan HD , Wu JL ', et al. The c orrelation b etween d ecreased o rnithine l evel and a lleviation of r heumatoid a rthritis p atients a ssessed by a r andomized, p lacebo- c ontrolled, d ouble- b lind c linical t rial of s inomenine.  Engineering   2022,16(9):93-99

Papers 5： Zhang Y, Du L, Wang C, et al. Neddylation is a novel therapeutic target for lupus by regulating double negative T cell homeostasis. Signal Transduct Target Ther. 2024 Jan 15;9(1):18.

Intellectual Property Name

A Tripterine Derivative, Its Preparation Method, and Application ; CN202211445414.6

Use of glycan as biomarkers for autoimmune diseases ;  US 10,234,454 B2

Sinomenium acutum; ISO4154：2022 ; International Organization for Standardization